TABLE 2.

Mean Symptoms Reduction from Pretreatment and 95% Confidence Intervals at Posttreatment and at Follow-Up Both for Videoconference and Face-to-Face Cognitive-Behavioral Therapy

	Face-to-face		Videoconference
	M	95% CI	M	95% CI
At follow-up (ITT results)	n = 32		n = 16
MPSS-total	−23.0	−32.1 to −13.8	−22.8	−34.7 to −10.9
MPSS-fr	−9.5	−13.4 to −5.5	−9.3	−14.1 to −4.6
MPSS-se	−13.5	−18.8 to −8.1	−13.5	−20.8 to −6.1
BDI	−7.2	−11.0 to −3.3	−6.5	−11.7 to −1.3
BAI	−3.7	−7.4 to 0.1	−6.2	−11.9 to −0.4
SF12-physical	1.8	0.2 to 3.5	5.2	2.4 to 7.9
SF12-mental	5.5	1.7 to 9.3	4.1	−0.7 to 8.9
At posttreatment (ITT results)	n = 23		n = 12
MPSS-total	−24.6	−34.2 to −15.0	−17.6	−29.0 to −6.3
MPSS-fr	−10.4	−14.5 to −6.3	−7.0	−11.6 to −2.4
MPSS-se	−14.2	−19.8 to −8.5	−10.6	−17.6 to −3.7
BDI	−6.7	−11.4 to −2.0	−5.8	−11.2 to −0.4
BAI	−5.0	−8.5 to −1.5	−7.0	−12.7 to −1.3
SF12-physical	2.5	0.5 to 4.4	5.1	2.0 to 8.2
SF12-mental	5.8	1.5 to 10.0	4.0	0.0 to 8.0
Main as-treated results
MPSS-total (follow-up)	−33.4	−47.1 to −19.7	−38.1	−58.0 to −18.2
MPSS-total (posttreatment)	−33.8	−45.6 to −21.9	−25.3	42.2 to −8.5

Note. A negative effect implies a symptom reduction except for the SF-12, for which the logic is reversed.

ITT = intent-to-treat; MPSS = Modified PTSD Symptom Scale; BDI = Beck Depression Inventory; BAI = Beck Anxiety Inventory; SF12 = SF-12 Version 2.0 Health Survey.